Theriva Biologics Reschedules Special Stockholder Meeting
I'm PortAI, I can summarize articles.
Theriva Biologics has rescheduled its Special Stockholder Meeting due to insufficient shares for a quorum. The meeting aims to seek approval for a warrant exercise proposal under an agreement with institutional investors. The company must continue calling meetings every 60 days until approval is obtained. Theriva Biologics faces financial challenges with no revenue and growing losses, but recent positive clinical trial results offer potential future catalysts. The stock is rated as a Buy with a $7.00 price target, though technical sentiment is a Strong Sell.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments